Edition:
United States

Bayer AG (BAYGn.DE)

BAYGn.DE on Xetra

108.45EUR
11:35am EDT
Change (% chg)

€-3.30 (-2.95%)
Prev Close
€111.75
Open
€110.50
Day's High
€110.65
Day's Low
€107.20
Volume
4,446,867
Avg. Vol
1,998,188
52-wk High
€123.90
52-wk Low
€86.03

BAYGn.DE

Chart for BAYGn.DE

About

Bayer AG is a life science company. The Company's segments are Pharmaceuticals, Consumer Health, Animal Health and Covestro. The Pharmaceuticals segment focuses on prescription products, especially for cardiology and women's healthcare, and on specialty therapeutics in the areas of oncology, hematology and ophthalmology. The... (more)

Overall

Beta: 0.98
Market Cap(Mil.): €92,411.41
Shares Outstanding(Mil.): 826.95
Dividend: 2.70
Yield (%): 2.42

Financials

  BAYGn.DE Industry Sector
P/E (TTM): 19.77 11.67 15.75
EPS (TTM): 5.65 -- --
ROI: 8.57 -10.11 -8.37
ROE: 16.72 -9.91 -7.95

UPDATE 1-Bayer cuts profit forecast after consumer health headache

* Records negative crop science revenue in Latam (Adds details on consumer care, drop in shares, analyst comment)

6:48am EDT

Bayer crimps profit goal to below 10 pct growth on crop chemicals

FRANKFURT, July 27 Bayer, which is taking over U.S. seeds group Monsanto, cut its outlook for operating profit growth this year to below 10 percent, as it grapples to cope with disappointing demand for crop chemicals in Brazil.

1:56am EDT

EU mergers and takeovers (July 26)

BRUSSELS, July 26 The following are mergers under review by the European Commission and a brief guide to the EU merger process:

Jul 26 2017

BRIEF-Compugen discloses updates to collaborative activities with Bayer in immuno-oncology

* Compugen discloses updates to collaborative activities with bayer in immuno-oncology

Jul 26 2017

Campaign group Avaaz calls on EU to block Bayer's Monsanto deal

BRUSSELS Online campaigns group Avaaz has called on European Union antitrust regulators to block Bayer's purchase of Monsanto, saying it would hurt innovation and competition and push up prices.

Jul 24 2017

Campaign group Avaaz calls on EU to block Bayer's Monsanto deal

BRUSSELS Online campaigns group Avaaz has called on European Union antitrust regulators to block Bayer's purchase of Monsanto, saying it would hurt innovation and competition and push up prices.

Jul 24 2017

UPDATE 1-Campaign group Avaaz calls on EU to block Bayer's Monsanto deal

BRUSSELS, July 24 Online campaigns group Avaaz has called on European Union antitrust regulators to block Bayer's purchase of Monsanto, saying it would hurt innovation and competition and push up prices.

Jul 24 2017

BRIEF-Evotec gets milestone payment from Bayer on endometriosis

* Says Evotec and Bayer advance endometriosis programme into phase I clinical development and extend alliance

Jul 24 2017

Morphosys sees revenue boost from Janssen psoriasis drug

DUESSELDORF/FRANKFURT German biotech group Morphosys expects to receive royalties from psoriasis drug guselkumab for five months this year, its Chief Executive Simon Moroney said, after its licensee received U.S. regulatory approval.

Jul 14 2017

EU mergers and takeovers (July 14)

BRUSSELS, July 14 The following are mergers under review by the European Commission and a brief guide to the EU merger process:

Jul 14 2017

Earnings vs. Estimates